| Date | Acquired company | Acquiring company | Amount | Related |
|---|---|---|---|---|
| 2014-07-15 | Ockham (UK) | Chiltern (USA) | CRO Cancer - Oncology |
|
| 2014-07-14 | Abbott's non-U.S. developed markets specialty and branded generics business (USA - IL) | Mylan (USA - PA) | $5.3 billion (€3.9 billion) | Generics |
| 2014-07-11 | AesRx (USA - MA) | Baxter (USA - IL) | undisclosed | Orphan drugs Rare diseases |
| 2014-07-11 | Archimedes (UK) | Prostrakan (UK) | £230 million (€ 284.5 million) | Pain Cancer -Oncology Critical care |
| 2014-07-03 | AnalytiCon Discovery (Germany) | BRAIN (Germany) | undisclosed | |
| 2014-07-02 | Seragon Pharmaceuticals (USA - CA) | Roche (Switzerland) | $725 million, plus additional contingent payments of up to $1 billion based on achievement of certain predetermined milestones | Cancer - Oncology |
| 2014-07-02 | Furiex Pharmaceuticals (USA - NC) | Forest Laboratories (USA - NJ), an Actavis\' subsidiary (Ireland) | $1.1 billion, and up to approximately $360 million in a Contingent Value Right (CVR) | Gastroenterology Digestive diseases |
| 2014-07-01 | ViraCor-IBT Laboratories (USA) | Eurofins Scientific (Luxembourg) | $255 million (€184.27 million) | |
| 2014-07-01 | Merck’s ophthalmological products (USA) | Santen Pharmaceutical (Japan) | $600 million | Ophtalmology |
| 2014-06-30 | bluebird bio (USA) | Precision Genome Engineering - Pregenen (USA - WA) | up to $ 140 million | gene therapy immunotherapy gene editing |
| 2014-06-12 | Andromeda Biotech (Israel) | Hyperion Therapeutics (USA - CA) | Metabolic diseases |
|
| 2014-06-09 | Idenix (USA) | Merck&Co (USA) | $3.85 billion | Infectious diseases |
| 2014-06-03 | Genhelix plant (Spain) | mAbxience (Switzerland) | €10 million | bioproduction biosimilar drugs |
| 2014-06-02 | Genia Technologies (USA) | Roche (Switzerland) | $125 million in cash and up to $225 million in contingent payments depending on the achievement of certain milestones | Technology NGS genomics |
| 2014-05-28 | Euprotec (UK) | Evotec (Germany) | £2.15 million (€2.64 million) | CRO Infectious diseases |
| 2014-05-27 | Lab21 (UK) | Novacyt (France) | ||
| 2014-05-22 | Inspiro Medical (Germany) | OPKO Health (USA) | undisclosed | Medical device |
| 2014-05-21 | Keocyt (France) | Riemser Pharma (Germany) | undisclosed | specialty pharmaceuticals |
| 2014-05-15 | CombinatoRx Service Business and Assets from Zalicus (USA) | Horizon Discovery (UK) | £4.74 million ($8million) | |
| 2014-05-15 | Bayer Healthcare\'s Interventional device business (Germany - USA) | Boston Scientific (USA - MA) | $ 415 million (about € 300 million) | Medical devices Cardiovascular diseases |
